Tomas Philipson

9.0k total citations
127 papers, 4.5k citations indexed

About

Tomas Philipson is a scholar working on Economics and Econometrics, General Health Professions and Sociology and Political Science. According to data from OpenAlex, Tomas Philipson has authored 127 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Economics and Econometrics, 26 papers in General Health Professions and 12 papers in Sociology and Political Science. Recurrent topics in Tomas Philipson's work include Health Systems, Economic Evaluations, Quality of Life (46 papers), Pharmaceutical Economics and Policy (38 papers) and Global Health Care Issues (17 papers). Tomas Philipson is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (46 papers), Pharmaceutical Economics and Policy (38 papers) and Global Health Care Issues (17 papers). Tomas Philipson collaborates with scholars based in United States, United Kingdom and India. Tomas Philipson's co-authors include Richard A. Posner, Darius Lakdawalla, Pierre‐Yves Geoffard, John Cawley, Anupam B. Jena, Gary S. Becker, Dana P. Goldman, William H. Dow, Jay Bhattacharya and Avner Ahituv and has published in prestigious journals such as Contemporary Sociology A Journal of Reviews, American Economic Review and The Quarterly Journal of Economics.

In The Last Decade

Tomas Philipson

120 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomas Philipson United States 33 2.4k 1.1k 965 492 338 127 4.5k
Kosali Simon United States 36 2.8k 1.2× 2.5k 2.3× 771 0.8× 564 1.1× 597 1.8× 186 5.4k
Jishnu Das United States 44 1.4k 0.6× 1.6k 1.4× 368 0.4× 878 1.8× 380 1.1× 141 6.0k
Jeffrey S. Hammer United States 32 1.3k 0.6× 1.1k 1.0× 228 0.2× 789 1.6× 146 0.4× 102 4.9k
Abbas Bhuiya Bangladesh 39 625 0.3× 1.8k 1.6× 412 0.4× 528 1.1× 887 2.6× 156 5.1k
David Canning United States 45 4.0k 1.7× 3.0k 2.7× 543 0.6× 1.4k 2.8× 915 2.7× 183 9.4k
Jed Friedman United States 28 727 0.3× 789 0.7× 227 0.2× 703 1.4× 307 0.9× 113 2.8k
Bas Donkers Netherlands 35 1.7k 0.7× 551 0.5× 192 0.2× 1.3k 2.7× 255 0.8× 93 5.0k
Alok Bhargava United States 25 1.8k 0.8× 684 0.6× 385 0.4× 454 0.9× 94 0.3× 83 3.7k
Joan Costa‐Font United Kingdom 42 1.5k 0.6× 1.9k 1.7× 528 0.5× 1.1k 2.2× 711 2.1× 352 6.0k
Pascaline Dupas United States 28 2.1k 0.9× 570 0.5× 170 0.2× 884 1.8× 171 0.5× 73 5.1k

Countries citing papers authored by Tomas Philipson

Since Specialization
Citations

This map shows the geographic impact of Tomas Philipson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomas Philipson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomas Philipson more than expected).

Fields of papers citing papers by Tomas Philipson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomas Philipson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomas Philipson. The network helps show where Tomas Philipson may publish in the future.

Co-authorship network of co-authors of Tomas Philipson

This figure shows the co-authorship network connecting the top 25 collaborators of Tomas Philipson. A scholar is included among the top collaborators of Tomas Philipson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomas Philipson. Tomas Philipson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Philipson, Tomas, et al.. (2023). The aggregate value of cancer screenings in the United States: full potential value and value considering adherence. BMC Health Services Research. 23(1). 829–829. 26 indexed citations
2.
Yin, Wesley, et al.. (2017). Association Between Breast Cancer Disease Progression and Workplace Productivity in the United States. Journal of Occupational and Environmental Medicine. 59(2). 198–204. 18 indexed citations
3.
Geoffard, Pierre‐Yves & Tomas Philipson. (2016). Disease Eradication: Private versus Public Vaccination. American Economic Review. 87(1). 222–230. 84 indexed citations
4.
Sun, Eric, Anupam B. Jena, Darius Lakdawalla, et al.. (2015). An economic evaluation of the war on cancer. RePEc: Research Papers in Economics. 1 indexed citations
5.
Lakdawalla, Darius, et al.. (2014). Effect of Oral Nutritional Supplements On Hospital Outcomes in Patients Aged 65+ With Congestive Heart Failure. Value in Health. 17(7). A503–A503. 1 indexed citations
6.
Philipson, Tomas, Mark T. Linthicum, & Julia Thornton Snider. (2014). Tutorial on Health Economics and Outcomes Research in Nutrition. Journal of Parenteral and Enteral Nutrition. 38(2S). 5S–16S. 6 indexed citations
7.
Lakdawalla, Darius, Julia Thornton Snider, Mark T. Linthicum, et al.. (2014). Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?. Forum for Health Economics & Policy. 17(2). 131–151. 8 indexed citations
8.
Stevens, Warren, et al.. (2014). A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies. Forum for Health Economics & Policy. 17(1). 21–52. 4 indexed citations
9.
Lü, Yang, et al.. (2012). Dynamic cost-effectiveness of oncology drugs.. PubMed. 18(11 Suppl). S249–56. 12 indexed citations
10.
Jena, Anupam B. & Tomas Philipson. (2012). Endogenous cost-effectiveness analysis and health care technology adoption. Journal of Health Economics. 32(1). 172–180. 30 indexed citations
11.
Lakdawalla, Darius & Tomas Philipson. (2009). The growth of obesity and technological change. Economics & Human Biology. 7(3). 283–293. 238 indexed citations
12.
Philipson, Tomas, et al.. (2005). Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts. National Bureau of Economic Research. 7 indexed citations
13.
Philipson, Tomas. (2005). Government perspective: food labeling. American Journal of Clinical Nutrition. 82(1). 262S–264S. 21 indexed citations
14.
Berndt, Ernst R., et al.. (2005). Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nature Reviews Drug Discovery. 4(7). 545–554. 63 indexed citations
15.
Philipson, Tomas, et al.. (2004). Between- vs. Within-Patent Competition. SSRN Electronic Journal. 1 indexed citations
16.
Berndt, Ernst R., et al.. (2004). Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process. Forum for Health Economics & Policy. 8(1). 3 indexed citations
17.
Lakdawalla, Darius & Tomas Philipson. (1998). Nonprofit Production and Competition. National Bureau of Economic Research. 41 indexed citations
18.
Philipson, Tomas & William H. Dow. (1998). Infectious disease transmission and infection-dependent matching. Mathematical Biosciences. 148(2). 161–180. 11 indexed citations
19.
Dow, William H., Tomas Philipson, Xavier Sala-i-Martín, & Jessica Holmes. (1997). Health investment complementarities under competing risks. Repositori digital de la UPF (Universitat Pompeu Fabra). 1 indexed citations
20.
Philipson, Tomas & Gary S. Becker. (1996). Mortality Contingent Claims, Health Care, and Social Insurance. National Bureau of Economic Research. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026